ACON Aclarion, Inc.

Nasdaq aclarion.com


$ 8.20 $ 0.00 (0 %)    

Tuesday, 21-Oct-2025 07:58:15 EDT
QQQ $ 611.27 $ -0.40 (-0.07 %)
DIA $ 467.35 $ 0.28 (0.06 %)
SPY $ 671.68 $ 0.22 (0.03 %)
TLT $ 92.06 $ 0.07 (0.08 %)
GLD $ 388.77 $ 2.25 (0.58 %)
$ 8.18
$ 7.99
$ 7.85 x 20
$ 8.20 x 400
-- - --
$ 6.20 - $ 1,294,818.89
33,862
na
4.76M
$ -14,681,812.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 04-09-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-25-2023 06-30-2023 10-Q
10 07-03-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 06-06-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aclarion-highlights-accelerating-growth-133m-cash-balance-and-ai-driven-biomarker-validation-progress

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility...

 aclarion-participated-in-the-international-society-of-pain-and-neuroscience-annual-meeting-announces-use-of-mr-spectroscopy-for-identifying-biomarkers-of-discogenic-pain

Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians differentiate b...

 aclarion-begins-pivotal-clarity-trial-to-test-nociscans-impact-on-chronic-low-back-pain-surgeries

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is le...

 ascendiant-capital-maintains-buy-on-aclarion-raises-price-target-to-22

Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $20 to $22.

 aclarion-q2-eps-275-misses-226-estimate-sales-19319k-miss-30000k-estimate

Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.75) per share which missed the analyst consensus estimate of $(2.26) by...

Core News & Articles

Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), today announced that in follow up to the ...

 aclarion-launches-major-us-trial-to-test-ai-tool-that-could-improve-spine-surgery-for-chronic-back-pain

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is le...

 aclarion-john-lorbiecki-to-retire-as-cfo-company--expects-to-appoint-new-cfo-by-q3-2025

https://www.sec.gov/Archives/edgar/data/1635077/000168316825004669/aclarion_8k.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION